Search results
Results from the WOW.Com Content Network
For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why. A ...
America's Health Rankings started in 1990 and is the longest-running annual assessment of the nation's health on a state-by-state basis. It is founded on the World Health Organization holistic definition of health, which says health is a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.
But as CNBC reports, an increase in major medical claims and the adoption of GLP-1 drugs used to treat conditions like Type 2 diabetes and obesity are driving costs up for everyone.
Getting diagnosed with type 2 diabetes before the age of 50 may increase one's risk of developing dementia by 1.9 times, a new study has found. ... Upon analysis, Wu and her team found that ...
The American Diabetes Association (ADA) is a United States-based nonprofit that seeks to educate the public about diabetes and to help those affected by it through funding research to manage, cure and prevent diabetes, including type 1 diabetes, type 2 diabetes, gestational diabetes, and pre-diabetes. It is a network of 565,000 volunteers which ...
A 440-patient study of type I diabetes ran in 2020 and 2021 using a device configuration that delivered only insulin in comparison to standard of care; device use led to better circulating glucose control (measured by continuous monitoring) and a reduction in glycated hemoglobin (versus no change for the standard of care group). [11]
Lilly answered with Mounjaro and Zepbound, approved in 2022 and 2023 for diabetes and weight loss, respectively. They use the active ingredient tirzepatide, which mimics not just GLP-1 but another ...
Recent studies have also attributed to Medicaid expansion an increase in use of smoking cessation medications, cervical cancer screening, and colonoscopy, as well as an increase in the percentage of early-stage diagnosis of all cancers and the rate of cancer surgery for low-income patients.